Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.26, $0.01 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $88.4 million versus the consensus estimate of $87.28 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.